Literature DB >> 23227587

Individual response to drug therapy: bases and study approaches.

Rafael Baltazar Reyes León-Cachón1, Jorge Angel Ascacio-Martínez, Hugo Alberto Barrera-Saldaña.   

Abstract

Genomic variation largely explains the differences in an individual's response to drug treatments. A field of genomic medicine focuses on the identification of genetic polymorphisms and gene mutations involved in the development and progression of disease. Another part focuses on the development of genetic tests to accompany medical prescriptions, to predict how certain patients respond to therapy with a given pharmacological agent. The field of predicting responses to drugs has different strategies and methods, among which we find: the use of liver microsomes, cell models, monitoring of probe drugs, assays with recombinant proteins and recently the use of microarray platforms or DNAchips.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23227587

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  6 in total

1.  Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants.

Authors:  C Lee Ventola
Journal:  P T       Date:  2013-09

2.  Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population.

Authors:  Sarahí Herrera-González; Denisse Aideé Martínez-Treviño; Marcelino Aguirre-Garza; Magdalena Gómez-Silva; Hugo Alberto Barrera-Saldaña; Rafael Baltazar Reyes León-Cachón
Journal:  Biomed Rep       Date:  2017-10-25

3.  From saliva to SNP: non-invasive, point-of-care genotyping for precision medicine applications using recombinase polymerase amplification and giant magnetoresistive nanosensors.

Authors:  Ana Sofia de Olazarra; Dana Lee Cortade; Shan X Wang
Journal:  Lab Chip       Date:  2022-05-31       Impact factor: 7.517

Review 4.  Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives.

Authors:  Muhammad Younas; Christophe Hano; Nathalie Giglioli-Guivarc'h; Bilal Haider Abbasi
Journal:  RSC Adv       Date:  2018-08-22       Impact factor: 4.036

5.  A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

Authors:  Rafael B R León-Cachón; Jorge A Ascacio-Martínez; María E Gamino-Peña; Ricardo M Cerda-Flores; Irene Meester; Hugo L Gallardo-Blanco; Magdalena Gómez-Silva; Everardo Piñeyro-Garza; Hugo A Barrera-Saldaña
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

6.  Personalized medicine: myth or reality? The position of Russian clinical pharmacologists.

Authors:  Anna S Zhestovskaja; Vladimir G Kukes; Dmitry A Sychev
Journal:  EPMA J       Date:  2013-05-11       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.